Oruka Therapeutics says Jacob Ma-Weaver resigned from the board

Form: 8-K
Filed: Sep 5, 2024, 5:18 pm ET
Period: Aug 29, 2024
Importance: Major
Accession: 0001213900-24-076184
Document: 8-K
Exhibit 10.10: Oruka Therapeutics, Inc. 2024 stock incentive plan
Exhibit 10.11: Oruka Therapeutics, Inc. 2024 employee stock purchase plan
Exhibit 10.13: Second amendment to amended and Restated Oruka Therapeutics, Inc. 2024 equity…
Exhibit 10.16: Form of employee warrant agreement
Exhibit 10.25: Consulting agreement, effective as of August 30, 2024, by and between Oruka…
Exhibit 99.1: Press release, issued on September 3, 2024

Signs a material agreement (1.01)
Completes an acquisition or sale of assets (2.01)
Reports quarterly results (2.02)
Changes shareholder rights (3.03)
Changes its auditor (4.01)
Reports a change in control (5.01)
Reports an executive or board change (5.02)
Amends its charter or bylaws (5.03)
Changes its ethics code (5.05)
Changes its shell company status (5.06)
Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.